Oct 202017
 

Authors of the new study included (left to right): Susana Valente, Cari F. Kessing and Chuan Li.

In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively suppresses production of the virus in chronically infected cells, and prevents viral rebound, even when those infected cells are subjected to vigorous stimulation.

The study, led by TSRI Associate Professor Susana Valente, was published online Oct. 17 before print in the journal Cell Reports.

“No other anti-retroviral used in the clinic today is able to completely suppress viral production in infected cells in vivo,” Valente said. “When combining this drug with the standard cocktail of anti-retrovirals used to suppress infection in humanized mouse models of HIV-1 infection, our study found a drastic reduction in virus RNA present—it is really the proof-of-concept for a ‘functional cure.’”

Valente, a pioneer in this new approach, calls it “Block-and-Lock”—the approach blocks reactivation of the virus in cells, even during treatment interruptions, and locks HIV into durable state of latency.

Valente and her colleagues use a derivative of a natural compound called didehydro-Cortistatin A (dCA), which blocks replication in HIV-infected cells by inhibiting the viral transcriptional activator, called Tat, halting viral production, reactivation and replenishment of the latent viral reservoir.

“Combining dCA with anti-retroviral therapy accelerates HIV-1 suppression and prevents viral rebound after treatment interruption, even during strong cellular activation,” Valente said. “It’s important to note that our study uses the maximum tolerable dose of the drug—with virtually no side effects.”

The scientists studied the combination therapy in a mouse model of HIV latency and persistence. Once the combined treatment regimen was halted, viral rebound was delayed up to 19 days, compared with just seven days in mouse models receiving only anti-retroviral treatment.

“This demonstrates the potential of ‘block-and-lock’ strategies,” said TSRI Research Associate Cari F. Kessing, co-first author of the study. “This study shows that a ‘functional cure’ approach can succeed in reducing residual virus in the blood during anti-retroviral treatment and limiting viral rebound during treatment interruption.”

“In half of the dCA treated mice, the virus was undetectable for 16 days after all treatment was halted,” said the University of North Carolina’s Christopher Nixon, another first author.

“We blocked Tat, and the cell’s machinery did the rest,” said TSRI Research Associate Chuan Li, a coauthor of the study. “The result was that the HIV promoter becomes repressed.”

Valente pointed out that the animal models were exposed to just a single month of treatment. “That’s a relatively short period of time,” she said. “We think longer treatments will result in longer, or even permanent, rebound delays. The question is how long? We’re studying that now.”

Because any viral rebound of HIV comes with a host of adverse effects, Valente noted, blocking that rebound would automatically reduce those effects.

“This is the only class of drugs that stops infected cells from making viruses outright,” said Valente. “All current antivirals work later in the viral lifecycle, so only a HIV transcriptional inhibitor like dCA can stop the side effects of low-level virus production.”

Learn more: New Research Opens the Door to ‘Functional Cure’ for HIV

 

The Latest on: HIV
  • SPONSORED: Early treatment helping HIV positive people to live longer, healthier lives
    on November 23, 2017 at 10:30 pm

    Kagaju hurries to join a group of young ladies sitting in a circle. It is evident that members of the group are eager to start their meeting. One can hardly know that this group of young women is formed by mothers, who, at an early age, became victims of ... […]

  • FDA approves first 2-drug HIV regimen
    on November 23, 2017 at 8:11 pm

    NEW YORK – The U.S. Food and Drug Administration on Tuesday approved the first two-drug regimen to treat HIV, the virus that causes AIDS, aimed at easing the side effects for long-term patients who are on the standard treatment involving three or more drugs. […]

  • ‘Life Now, Yes Life, No HIV’
    on November 23, 2017 at 7:02 pm

    Morung Express NewsMorung Express NewsKohima | November 23The Nagaland State AIDS Control Society (NSACS) will be conducting its multi-media campaign (MMC) 2017-18 under the theme ‘Life Now, Yes life, NO HIV’ to promote awareness, compassion, education ... […]

  • Man with HIV in Escambia County, Fla. infects several women
    on November 23, 2017 at 2:25 pm

    Escambia County Sheriff’s Office has arrested a man for having sex with at least three women and not informing them he was HIV positive. The incidents happened between September 2016 and October 2017 in Escambia County and Pensacola per the warrant. […]

  • First outpatient HIV clinic opens in east side, cases on the rise
    on November 23, 2017 at 2:15 pm

    SAN ANTONIO - Bexar County has a serious problem when it comes to the number of reported HIV cases. According to recent data, the county continues to uptick higher than the state and national average. The San Antonio Aids Foundation recently opened its ... […]

  • Meet the Brave Mothers Working to End HIV, One Conversation at a Time
    on November 23, 2017 at 2:14 pm

    Irene Nkosi of Pretoria, South Africa, was 16 when she first became a parent. She was later the victim of a horrific rape for which her attacker was never jailed. When her daughter was 6 years old, she became pregnant again. That’s when she discovered ... […]

  • Why I Married My Boyfriend Who Infected Me With HIV — 30-Year-Old Postgraduate Student
    on November 23, 2017 at 11:59 am

    Her misery started after a scary dream on June 24, 2016. It was five months to her wedding. Thirty-year-old Talatu John (not real name), a postgraduate student of a university in the North, woke up feeling disturbed. It was not the first time she had ... […]

  • Why Is Charlotte the HIV Capitol Of North Carolina?
    on November 23, 2017 at 11:37 am

    New Mecklenburg County, North Carolina's health director, Gibbie Harris, got flack for saying the reason Charlotte has such high rates of HIV transmission because it's a "party town" where tourists sometimes leave behind things (like sexually-transmitted ... […]

  • Four big insights into HIV/AIDS that provide hope of finding a vaccine
    on November 23, 2017 at 6:24 am

    Thumbi Ndung'u receives funding from the Gates Foundation, Gilead Sciences, the South Africa National Research Foundation, The National Institutes of Health, the Victor Daitz Foundation and the Wellcome Trust. He is affiliated with the University of ... […]

via Google News and Bing News

Other Interesting Posts

Leave a Reply

%d bloggers like this: